natgillin/translations-raw huggingface dataset:
In pre-specified final analyses of the LONG TERM study, treatment-emergent CV events confirmed by adjudication occurred in 72 of 1550 (4.6%) patients in the alirocumab group and in 40 of 788 (5.1%) patients in the placebo group; MACE confirmed by adjudication were reported in 27 of 1550 (1.7%) patients in the alirocumab group and 26 of 788 (3.3%) patients in the placebo group.
Prema unaprijed određenim konačnim analizama podataka iz ispitivanja LONG TERM, neovisno potvrđeni KV događaji koji su se javili tijekom liječenja zabilježeni su u 72 od 1550 (4,6%) bolesnika u skupini liječenoj alirokumabom te u 40 od 788 (5,1%) bolesnika u skupini koja je primala placebo; neovisno potvrđeni MACE događaji bili su prijavljeni u 27 od 1550 (1,7%) bolesnika liječenih alirokumabom te 26 od 788 (3,3%) onih koji su primali placebo.
In preclinical and clinical studies, Tecfidera demonstrated anti-inflammatory and immunomodulatory properties.
U pretkliničkim i kliničkim ispitivanjima Tecfidera je pokazala protuupalna i imunomodulacijska svojstva.
In preclinical disease models of lung fibrosis nintedanib exerts potent anti-fibrotic and anti- inflammatory activity.
U pretkliničkim modelima plućne fibroze nintedanib ispoljava potentnu protufibroznu i protuupalnu aktivnost.
In preclinical studies it has been shown that renal clearance is minimal (up to 2% of total clearance), and does not affect the serum half-life.
Pretkliničke studije pokazale su da je bubrežni klirens minimalan (do 2% od ukupnog klirensa) i da ne utječe na poluvijek darbepoetina alfa u serumu.
In preclinical studies regorafenib has demonstrated potent antitumour activity in a broad spectrum of tumour models including colorectal and gastrointestinal stromal tumour models which is mediated by its anti-angiogenic and anti-proliferative effects.
U pretkliničkim ispitivanjima regorafenib je pokazao snažno antitumorsko djelovanje na široki spektar tumorskih modela, uključujući i modele kolorektalnog i gastrointestinalnih stromalnih tumora, koje je posredovano njegovim antiangiogenim i antiproliferativnim učincima.
In preclinical studies, no effects of Micardis on male and female fertility were observed.
U nekliničkim ispitivanjima učinci Micardisa na plodnost muškaraca i žena nisu uočeni.
In preclinical studies, no effects of sapropterin on male and female fertility were observed.
U pretkliničkim ispitivanjima nisu opaženi učinci sapropterina na mušku i žensku plodnost.
In preclinical studies, no effects of telmisartan and hydrochlorothiazide on male and female fertility were observed.
U pretkliničkim ispitivanjima nisu primijećeni učinci telmisartana i hidrokorotiazida na mušku i žensku plodnost.
In preclinical studies, no effects of telmisartan on male and female fertility were observed.
U nekliničkim ispitivanjima učinci lijeka Telmisartan Actavis na plodnost muškaraca i žena nisu uočeni.
In preclinical studies, no effects of telmisartan on male and female fertility were observed.
U pretkliničkim ispitivanjima učinci telmisartana na plodnost muškaraca i žena nisu uočeni.
In preclinical studies, Nuwiq was used to safely and effectively restore haemostasis in dogs with haemophilia.
U nekliničkim ispitivanjima lijek Nuwiq se koristio za siguran i učinkovit povrat hemostaze u pasa s hemofilijom.
In preclinical studies, olanzapine exhibited a range of receptor affinities (Ki < 100 nM) for serotonin 5 HT2A/2C, 5 HT3, 5 HT6; dopamine D1, D2, D3, D4, D5; cholinergic muscarinic receptors M1-M5; α1 adrenergic; and histamine H1 receptors.
U ispitivanju pomoću pozitronske emisijske tomografije (PET), jednostruka oralna doza (10 mg) olanzapina u zdravih dobrovoljaca dovela je do većeg zauzimanja 5 HT2A nego dopaminskih D2 receptora.
In preclinical studies, olanzapine exhibited a range of receptor affinities (Ki < 100 nM) for serotonin 5 HT2A/2C, 5 HT3, 5 HT6; dopamine D1, D2, D3, D4, D5; cholinergic muscarinic receptors M1-M5; α1 adrenergic; and histamine H1 receptors.
U pretkliničkim ispitivanjima, olanzapin je pokazao raspon afiniteta za receptore (Ki < 100 nM) serotonina 5 HT2A/2C, 5 HT3, 5 HT6; dopamina D1, D2, D3, D4, D5; kolinergičke muskarinske receptore M1–M5; α1 adrenergičke; i histaminske H1 receptore.
In preclinical studies, olanzapine exhibited a range of receptor affinities (Ki < 100 nM) for serotonin 5 HT2A/2C, 5 HT3, 5 HT6; dopamine D1, D2, D3, D4, D5; cholinergic muscarinic receptors M1-M5; 1 adrenergic; and histamine H1 receptors.
U pretkliničkim ispitivanjima olanzapin je pokazao raspon afiniteta za receptore (Ki < 100 nM) serotonina 5HT2A/2C, 5HT3, 5HT6; dopamina D1, D2, D3, D4, D5; kolinergičke muskarinske receptore M1-M5; α1 adrenergičke; i histaminske H1 receptore.
In preclinical studies, olanzapine exhibited a range of receptor affinities (Ki < 100 nM) for serotonin 5 HT2A/2C, 5 HT3, 5 HT6; dopamine D1, D2, D3, D4, D5; cholinergic muscarinic receptors M1-M5; 1 adrenergic; and histamine H1 receptors.
U pretkliničkim ispitivanjima, olanzapin je pokazao raspon afiniteta za receptore (Ki < 100 nM) serotonina 5HT2A/2C, 5HT3, 5HT6; dopamina D1, D2, D3, D4, D5; kolinergičke muskarinske receptore M1-M5; α1 adrenergičke; i histaminske H1 receptore.
In preclinical studies, olanzapine exhibited a range of receptor affinities (Ki < 100 nM) for serotonin 5HT2A/2C, 5HT3, 5HT6; dopamine D1, D2, D3, D4, D5; cholinergic muscarinic receptors M1-M5; α 1 adrenergic; and histamine H1 receptors.
U pretkliničkim ispitivanjima olanzapin je pokazao raspon afiniteta za receptore (Ki < 100 nM) serotonina 5HT2A/2C, 5HT3, 5HT6; dopamina D1, D2, D3, D4, D5; kolinergičke muskarinske receptore M1-M5; α1 adrenergičke; i histaminske H1 receptore.
In preclinical studies, olanzapine exhibited a range of receptor affinities (Ki < 100 nM) for serotonin 5HT2A/2C, 5HT3, 5HT6; dopamine D1, D2, D3, D4, D5; cholinergic muscarinic receptors M1-M5; α 1 adrenergic; and histamine H1 receptors.
U pretkliničkim ispitivanjima, olanzapin je pokazao raspon afiniteta za receptore (Ki < 100 nM) serotonina 5HT2A/2C, 5HT3, 5HT6; dopamina D1, D2, D3, D4, D5; kolinergičke muskarinske receptore M1-M5; α1 adrenergičke; i histaminske H1 receptore.
In preclinical studies, olanzapine exhibited a range of receptor affinities (Ki < 100 nM) for serotonin 5HT2A/2C, 5HT3, 5HT6; dopamine D1, D2, D3, D4, D5; cholinergic muscarinic receptors M1-M5; α1 adrenergic; and histamine H1 receptors.
U pretkliničkim ispitivanjima olanzapin je pokazao raspon afiniteta za receptore (Ki < 100 nM) serotonina 5HT2A/2C, 5HT3, 5HT6; dopamina D1, D2, D3, D4, D5; kolinergičke muskarinske receptore M1-M5; α1 adrenergičke; i histaminske H1 receptore.
In preclinical studies, olanzapine exhibited a range of receptor affinities (Ki < 100 nM) for serotonin 5HT2A/2C, 5HT3, 5HT6; dopamine D1, D2, D3, D4, D5; cholinergic muscarinic receptors M1-M5; α1 adrenergic; and histamine H1 receptors.
U pretkliničkim ispitivanjima, olanzapin je pokazao raspon afiniteta za receptore (Ki < 100 nM) serotonina 5HT2A/2C, 5HT3, 5HT6; dopamina D1, D2, D3, D4, D5; kolinergičke muskarinske receptore M1-M5; α1 adrenergičke; i histaminske H1 receptore.
In preclinical studies, olanzapine exhibited a range of receptor affinities (Ki < 100 nM) for serotonin 5HT2A/2C, 5HT3, 5HT6; dopamine D1, D2, D3, D4, D5; cholinergic muscarinic receptors M1-M5; 1 adrenergic; and histamine H1 receptors.
U pretkliničkim ispitivanjima, olanzapin je pokazao raspon afiniteta za receptore (Ki < 100 nM) serotonina 5HT2A/2C, 5HT3, 5HT6; dopamina D1, D2, D3, D4, D5; kolinergičke muskarinske receptore M1-M5; α1 adrenergičke; i histaminske H1 receptore.
In preclinical studies, olanzapine exhibited a range of receptor affinities (Ki; < 100 nM) for serotonin 5- HT2A/2C, 5-HT3, 5-HT6; dopamine D1, D2, D3, D4, D5; cholinergic muscarinic receptors M1-M5; -1 adrenergic; and histamine H1 receptors.
U nekliničkim ispitivanjima olanzapin je pokazao afinitet prema brojnim receptorima (Ki < 100 nM) za serotonin 5-HT2A/2C, 5-HT3, 5-HT6; dopamin D1, D2, D3, D4, D5; kolinergičke muskarinske receptore M1-M5; α1 adrenergičke; i histaminske H1 receptore.
In preclinical studies, olanzapine exhibited a range of receptor affinities (Ki< 100 nM) for serotonin 5HT2A/2C, 5HT3, 5HT6; dopamine D1, D2, D3, D4, D5; cholinergic muscarinic receptors M1-M5; α 1 adrenergic; and histamine H1 receptors.
U pretkliničkim ispitivanjima olanzapin je pokazao raspon afiniteta za receptore (Ki < 100 nM) serotonina 5HT2A/2C, 5HT3, 5HT6; dopamina D1, D2, D3, D4, D5; kolinergičke muskarinske receptore M1-M5; α1 adrenergičke; i histaminske H1 receptore.
In preclinical studies, the absorption of enzalutamide was increased when dissolved in caprylocaproyl macrogolglycerides.
U prekliničkim je ispitivanjima apsorpcija enzalutamida bila povećana kada se rastopio u kaprilokaproil makrogolgliceridima.
In preclinical studies, there was no indication of racemisation of pregabalin
U nekliničkim istraživanjima nije bilo znakova racemizacije S-enantiomera pregabalina u
In preclinical studies, there was no indication of racemisation of pregabalin S-enantiomer to the R-enantiomer.
U nekliničkim istraživanjima nije bilo znakova racemizacije S-enantiomera pregabalina u R- enantiomer.
In pregnant rabbits given oral doses of sevelamer hydrochloride by gavage during organogenesis, an increase of early resorptions occurred in the high-dose group (human equivalent dose twice the maximum clinical trial dose).
U skotnih ženki kunića kojima je sevelamerklorid primijenjen peroralno kroz sondu tijekom organogeneze došlo je do povećanja rane resorpcije u skupini koja je dobila visoku dozu (odgovarajuća doza za ljude dvostruko je veća od maksimalne doze iz kliničkog ispitivanja).
In pregnant rabbits, decreased foetal body weight, increased abortions, increased incidence of incomplete ossification and skeletal malformations were seen at sub-clinical exposures based on AUC).
U skotnih ženki kunića primijećeni su smanjena tjelesna težina ploda, povećan broj pobačaja, povećana incidencija nepotpunog okoštavanja i koštanih malformacija pri izloženostima koje su bile manje od kliničke izloženosti na temelju AUC-a.
In pregnant rabbits, gross lesions of the stomach and intestines were observed in dead or moribund does at maternal doses 2 and 4 times the highest dose administered in the definitive embryo- development study.
U skotnih ženki kunića opažene su velike lezije na želucu i crijevima u mrtvih ženki kunića ili ženki kunića na umoru pri dozama koje su bile 2 odnosno 4 puta veće od najviše doze primijenjene u zaključnom ispitivanju embrionalnog razvoja.
In pregnant rabbits, gross lesions of the stomach and intestines were observed in dead or moribund does at maternal doses 2 and 4 times the highest dose administered in the definitive embryo- development study.
U skotnih ženki kunića opažene su velike lezije na želucu i crijevima u mrtvih ženki kunića ili ženki kunića na umoru pri maternalnim dozama koje su bile 2 ili 4 puta veće od najviše doze primijenjene u zaključnom ispitivanju embrionalnog razvoja.
In pregnant rabbits, no teratogenicity, embryotoxicity or fetotoxicity was observed at doses up to 240 mg/kg/day (approximately 23 times the MRHD on a mg/m2 basis.
U trudnih kunića, teratogenost, embriotoksičnost ili fetotoksičnost nisu opaženi pri dozama do 240 mg/kg/dan (približno 23 puta veća doza od MRHD na bazi mg/m2).
In pregnant rat, systemic administration of travoprost at doses more than 200 times the clinical dose during the period of organogenesis resulted in an increased incidence of malformations.
U trudnih štakorica, sustavna primjena travoprosta u dozama većim od 200 puta od kliničke doze tijekom razdoblje organogeneze, prouzrokuje povećanu incidenciju malformacija.
In pregnant rats and rabbits there were no major effects on embryo-foetal development.
U skotnih štakora i kunića nisu zamijećeni značajniji učinci na embrio-fetalni razvoj.
In pregnant rats, ibrutinib at a dose of 80 mg/kg/day was associated with increased post-implantation loss and increased visceral (heart and major vessels) malformations and skeletal variations with an exposure margin 14 times the AUC found in patients at a daily dose of 560 mg.
U skotnih štakora, ibrutinib pri dozi od 80 mg/kg/dan je bio povezan s povećanim postimplantacijskim gubitkom i povećanim visceralnim (srce i velike žile) malformacijama i promjenama kostura s granicom izloženosti 14 puta većom od AUC pronađenog u bolesnika pri dnevnoj dozi od 560 mg.
In pregnant rats, intravenous verteporfin doses of 10 mg/kg/day (approximately 40-fold human exposure at 6 mg/m2 based on AUCinf in female rats) were associated with an increased incidence of anophthalmia/microphthalmia and doses of 25 mg/kg/day (approximately 125-fold the human exposure at 6 mg/m2 based on AUCinf in female rats) were associated with an increased incidence of wavy ribs and anophthalmia/microphthalmia.
U gravidnih ženki štakora intravenske doze verteporfina od 10 mg/kg/dan (približno 40 puta veće od izloženosti u ljudi od 6 mg/m2 na temelju vrijednosti AUCinf u ženki štakora) bile su povezane s povišenom incidencijom anoftalmije/mikroftalmije, dok su doze od 25 mg/kg/dan (približno 125 puta veće od izloženosti u ljudi od 6 mg/m2 na temelju vrijednosti AUCinf u ženki štakora) bile povezane s povišenom incidencijom valovitih rebara i anoftalmije/mikroftalmije.
In pregnant rats, no evidence of teratogenicity, embryotoxicity, or fetotoxicity was observed at doses up to 300 mg/kg/day (approximately 15 times the MRHD on a mg/m2 basis in a 60 kg subject).
U trudnih štakorica, nisu opaženi dokazi za teratogenost, embriotoksičnost ili fetotoksičnost pri dozama do 300 mg/kg/dan (približno 15 puta veća doza od MRHD na bazi mg/m2 u ispitanika od 60 kg).
In pregnant rats, no maternal or fetal toxicity was observed at doses up to 575 micrograms/kg/day.
U skotnih štakora, nije uočena toksičnost za majku ili fetalna toksičnost u dozama do
In pregnant rats, no maternal or fetal toxicity was observed at doses up to 575 µg/kg/day.
U trudnih štakorica nije zabilježena toksičnost kod majke niti fetalna toksičnost pri dozama do 575 µg/kg/dan.
In pregnant rats, no maternal or fetal toxicity was observed at doses up to 575 μg/kg/day.
U gravidnih štakorica nije zabilježena toksičnost za majku ili fetalna toksičnost kod doza do
In pregnant rats, no maternal or foetal toxicity was observed at doses up to 575 µg/kg/day.
Kod gravidnih štakorica nije uočena maternalna ili fetalna toksičnost pri dozama do 575 µg/kg na dan.
In pregnant women treated with lamivudine, more than 1000 outcomes from first trimester and more than 1000 outcomes from second and third trimester exposure indicate no malformative and foeto/neonatal effect.
U trudnica liječenih lamivudinom, više od 1000 ishoda trudnoća nakon izlaganja lijeku u prvom tromjesečju te više od 1000 ishoda nakon izlaganja lijeku u drugom i trećem tromjesečju trudnoće ukazuju da lamivudin ne uzrokuje malformacije i da nema feto/neonatalni učinak.
In pregnant women, more than 800 outcomes after first trimester exposure and more than 1000 outcomes after second and third trimester exposure indicate no malformative and foetal /neonatal effect of abacavir.
Više od 800 ishoda nakon izloženosti trudnica u prvom tromjesečju i više od 1000 ishoda nakon izloženosti trudnica u drugom i trećem tromjesečju pokazuju da abakavir ne uzrokuje malformacije i nema učinka na fetus/novorođenče.
In premature infants with cholestatic hepatitis a prolonged caffeine elimination half-life with an increase of plasma levels above the normal limit of variation has been found suggesting a particular caution in the dosage of these patients (see sections 4.2 and 4.4).
U prerano rođene dojenčadi s kolestatskim hepatitisom pronađeno je produljeno poluvrijeme eliminacije kofeina, s povišenima razinama u plazmi iznad normalne granice varijacije, što znači da je potreban osobit oprez kod doziranja u tih bolesnika (vidjeti dijelove 4.2 i 4.4).
In preparing the solution, the following two-step process must be carried out in an aseptic manner according to local standards for handling cytotoxic/cytostatic medicines:
Kod pripreme otopine mora se provesti postupak u dva koraka na aseptički način u skladu s lokalnim standardima rukovanja citotoksičnim/citostatskim lijekovima.
In preterm infants born after at least 27 weeks of gestational age, the recommended immunisation series consists of four doses, each of 0.5ml.
U prijevremeno rođene dojenčadi, nakon barem 27 tjedana gestacije, preporučeni raspored imunizacije sastoji se od ukupno četiri doze, svaka od 0,5 ml.
In preterm newborn infants with insufficient clinical response to the recommended loading dose, a second loading dose of 10 -20 mg/kg maximum may be given after 24 hours.
U nedonoščadi s nedostatnim kliničkim odgovorom na preporučenu udarnu dozu može se nakon 24 sata dati druga udarna doza od najviše 10-20 mg/kg.
In preterm newborns ibuprofen significantly reduced plasma concentrations of prostaglandins and their metabolites, particularly PGE2 and 6-keto-PGF-1-alpha.
U nedonoščadi ibuprofen značajno smanjuje koncentraciju prostaglandina i njihovih metabolita u plazmi, osobito PGE2 i 6-keto-PGF-1-alfa.
In previously untreated patients, Arzerra plus chlorambucil was effective at increasing progression-free survival, with patients living on average for 22.4 months without their disease getting worse, compared with 13.1 in patients given chlorambucil alone.
Kod bolesnika koji nisu prethodno liječeni, lijek Arzerra u kombinaciji s klorambucilom pokazao se djelotvornim pri povećanju stope preživljenja bez progresije bolesti; bolesnici su u prosjeku živjeli 22,4 mjeseca bez pogoršanja bolesti, u usporedbi s 13,1 mjeseci kod bolesnika koji su primali monoterapiju klorambucilom.
In previously unvaccinated study participants who received one dose in year 1, efficacy was 57.7% (95% CI: 44.7, 67.9) against matched strains and 56.3% (95% CI: 43.1, 66.7) against all strains regardless of match, respectively, thus supporting the need for two doses of vaccine in previously unvaccinated children. eIn study participants who received 2 doses in year 1 and placebo in year 2, efficacy in year 2 was 56.2% (95% CI: 30.5, 72.7) against matched strains and 44.8% (95% CI: 18.2, 62.9) against all strains regardless of match, respectively, in D153-P501, thus supporting the need for second-season revaccination. fThe primary circulating strain was antigenically dissimilar from the H3N2 strain represented in the vaccine; efficacy against the mismatched A/H3N2 strain was 85.9% (95% CI: 75.3, 91.9).
Kod sudionika ispitivanja koji prethodno nisu bili cijepljeni, a koji su primili jednu dozu u 1. godini, djelotvornost je bila 57,7% (95% CI: 44,7; 67,9) naspram podudarnih sojeva te 56,3% (95% CI: 43,1; 66,7) naspram svih sojeva bez obzira na podudarnost, što podupire potrebu za primjenom dvije doze cjepiva u djece koja prethodno nisu cijepljena. e U sudionika ispitivanja koji su primili 2 doze u 1. godini i placebo u 2. godini, djelotvornost u 2. godini iznosila je 56,2% (95% CI: 30,5; 72,7) naspram podudarnih sojeva te 44,8% (95% CI: 18,2; 62,9) naspram svih sojeva bez obzira na podudarnost, u D153-P501, što podupire potrebu za ponovnim cijepljenjem u drugoj sezoni. f Primarni cirkulirajući soj bio je po antigenima različit od soja H3N2 koji je bio prisutan u cjepivu; djelotvornost naspram nepodudarnog soja A/H3N2 iznosila je 85,9% (95% CI: 75,3; 91,9).
In primary and secondary hyperparathyroidism too much PTH is produced by the parathyroid glands.
U primarnom i sekundarnom hiperparatireoidizmu paratireoidne žlijezde proizvode previše PTH-a.
In primary hypercholesterolaemia and mixed dyslipidaemia, Repatha was studied in 9 main studies involving around 7,400 adult patients, including patients with heterozygous familial disease.
U slučaju primarne hiperkolesterolemije i miješane dislipidemije, lijek Repatha ispitan je u 9 glavnih ispitivanja kojima je obuhvaćeno otprilike 7 400 odraslih osoba, uključujući bolesnike s heterozigotnom obiteljskom bolešću.
In principle, general dose recommendations also apply to patients aged 65 years and above.
U principu, općenite preporuke za doziranje također se odnose na bolesnike u dobi od 65 ili više godina.
In PROactive, a cardiovascular outcome study, 5,238 patients with type 2 diabetes mellitus and pre-existing major macrovascular disease were randomised to pioglitazone or placebo in addition to existing antidiabetic and cardiovascular therapy, for up to 3.5 years.
U PROactive ispitivanju kardiovaskularnog ishoda, 5238 bolesnika sa šećernom bolešću tipa 2 i postojećom velikom makrovaskulanom bolešću bilo je randomizirano u skupinu koja je primala pioglitazon i skupinu koja je primala placebo uz postojeću antidijabetičku i kardiovaskularnu terapiju, u trajanju do 3,5 godine.
In PROactive, a cardiovascular outcome study, 5238 patients with type 2 diabetes mellitus and pre- existing major macrovascular disease were randomised to pioglitazone or placebo in addition to existing antidiabetic and cardiovascular therapy, for up to 3.5 years.
U PROactive ispitivanju kardiovaskularnih ishoda, 5238 bolesnika sa šećernom bolešću tipa 2 i postojećom teškom makrovaskularnom bolešću bilo je randomizacijom raspodijeljeno u skupinu koja je primala pioglitazon i onu koja je primala placebo uz postojeću antidijabetičku i kardiovaskularnu terapiju u trajanju do 3,5 godine.
In PROactive, a cardiovascular outcome study, 5238 patients with type 2 diabetes mellitus and pre-existing major macrovascular disease were randomised to pioglitazone or placebo in addition to existing antidiabetic and cardiovascular therapy, for up to 3.5 years.
U PROactive ispitivanju kardiovaskularnog ishoda, 5238 bolesnika sa šećernom bolešću tipa 2 i velikim makrovaskulanim bolestima bilo je randomizirano u skupinu koja je primala pioglitazon i skupinu koja je primala placebo uz postojeću antidijabetičku i kardiovaskularnu terapiju, u trajanju do 3,5 godine.
In prospective studies, Streptococcus pneumoniae was estimated to be responsible for 30-50% of pneumonia cases.
U prospektivnim ispitivanjima procijenjeno je da 30-50% slučajeva upale pluća uzrokuje Streptococcus pneumoniae.
In protease inhibitor (PI) experienced patients the choice of Telzir should be based on individual viral resistance testing and treatment history (see section 5.1).
Kod bolesnika koji su primali inhibitore proteaze (IP) odabir lijeka Telzir treba temeljiti na individualnim testovima virusne rezistencije i podacima o ranijem liječenju (vidjeti dio 5.1).
In Protocol 003, anti-HPV antibody GMTs at Month 7 among 16- through 26-year-old boys and men (HM) were comparable to anti-HPV antibody GMTs among 16- through 26-year-old girls and women for HPV 6, 11, 16, 18, 31, 33, 45, 52 and 58.
U Protokolu 003, GMT-ovi protutijela na HPV u 7. mjesecu u dječaka i muškaraca u dobi od 16 do 26 godina (HM) bili su usporedivi s GMT-ovima protutijela na HPV u djevojaka i žena u dobi od 16 do 26 godina za tipove 6, 11, 16, 18, 31, 33, 45, 52 and 58 HPV-a.
In Protocol 020/GDS07C, anti-HPV antibody GMTs at Month 7 among 16- through 26-year-old boys and men (HM) were comparable to anti-HPV antibody GMTs among 16- through 26-year-old boys and men (HM) administered with the qHPV vaccine for HPV 6, 11, 16 and 18.
U Protokolu 020/GDS07C, GMT-ovi protutijela na HPV u 7. mjesecu u dječaka i muškaraca u dobi od 16 do 26 godina (HM) bili su usporedivi s GMT-ovima protutijela na HPV u dječaka i muškaraca u dobi od 16 do 26 godina (HM) u kojih je primijenjeno cjepivo qHPV, za tipove 6, 11, 16 i 18 HPV-a.
In PsA Study 1 and PsA Study 2, efficacy was maintained up to Week 52.
U prvom i drugom ispitivanju PsA djelotvornost se održala do 52. tjedna.
In PsA Study 2, among 200 patients initially randomised to Cosentyx 150 mg and 300 mg, 178 (89%) patients were still on treatment at Week 52.
U drugom ispitivanju PsA među 200 bolesnika prvobitno randomiziranih na Cosentyx 150 mg i 300 mg, 178 (89%) bolesnika bilo je još uvijek na terapiji u 52. tjednu.
In psoriasis and psoriatic arthritis clinical studies less than 8% of ustekinumab-treated patients developed antibodies to ustekinumab.
U kliničkim ispitivanjima psorijaze i psorijatičnog artritisa u manje od 8% bolesnika liječenih ustekinumabom, razvila su se protutijela na ustekinumab.